FDA Approves mFLUSIVA (influenza vaccine, mRNA) for the Prevention of Seasonal Influenza
RegulatoryapprovedmFLUSIVAPositive
AI Analysis
Summary
The FDA has approved Moderna's mFLUSIVA (mRNA-1010), an mRNA-based seasonal influenza vaccine for use in all adults. This represents a major regulatory milestone for Moderna's mRNA vaccine platform.
Outcome Details
FDA approval for use in all adults
Importance:9/10
Sentiment:
0.95
FDA approvalvaccinemRNAinfluenzaModerna
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 5, 2026 3:08 AM